ArticleAdvanced healthcare materials2026
Biomimetic Copper Nanoparticles Coated with ACE2-Overexpressing Membranes for Selective SARS-CoV-2 Neutralization and Disinfection.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative innate immune responses across major RNA and DNA viral infections: Mechanisms, immunopathology, and therapeutic perspectives.Human vaccines & immunotherapeutics · 2026Review
- Gold Nanoparticles for Antiviral Applications: Design Principles, Surface Engineering, and Mechanistic Insights.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The SARS-CoV-2 spike protein facilitates viral entry into host cells by binding to the human angiotensin-converting enzyme 2 (ACE2) receptor. To exploit this mechanism for therapeutic intervention, a liposome fusion-induced membrane exchange (LIME) strategy to generate biomimetic membrane-integrated liposomes (MILs) from ACE2-overexpressing mammalian cells was developed. Using engineered HeLa cells as a model, MILs have been successfully harvested that retained native surface proteins, including ACE2, as confirmed by immunogold TEM and Western blot analysis. These ACE2-presenting MILs were then coated onto copper nanoparticles (Cu NPs), creating biomimetic Cu@MIL nanostructures with dual functions, including selective viral capture via ACE2-mediated binding and neutralization, as well as potent antiviral activity from Cu NP disinfection. This synergistic platform effectively camouflages the nanomaterial with host-mimetic membranes, conferring targeted viral neutralization and disinfection capabilities. Our findings highlight the potential of Cu@MIL nanoparticles as a decoy-plus antiviral therapeutic for SARS-CoV-2, offering a promising strategy to combat COVID-19 and future pandemics of receptor-specific pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.